These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35274403)

  • 1. The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study.
    Howell J; Traeger MW; Williams B; Layton C; Doyle JS; Latham N; Draper B; Bramwell F; Membrey D; McPherson M; Roney J; Stoové M; Thompson AJ; Hellard ME; Pedrana A
    J Viral Hepat; 2022 May; 29(5):375-384. PubMed ID: 35274403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study.
    Williams B; Howell J; Doyle J; Thompson AJ; Draper B; Layton C; Latham N; Bramwell F; Membrey D; Mcpherson M; Roney J; Stoové M; Hellard ME; Pedrana A
    Int J Drug Policy; 2019 Oct; 72():91-98. PubMed ID: 31129023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility.
    MacIsaac MB; Whitton B; Hubble A; Cogger S; Penn M; Weeks A; Elmore K; Pemberton D; Anderson J; Howard R; McKeever U; Papaluca T; Hellard ME; Stoove M; Wilson D; Pedrana A; Doyle J; Clark N; Holmes J; Thompson AJ
    Med J Aust; 2023 Apr; 218(6):256-261. PubMed ID: 36919230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility.
    MacIsaac MB; Whitton B; Anderson J; Cogger S; Vella-Horne D; Penn M; Weeks A; Elmore K; Pemberton D; Winter RJ; Papaluca T; Howell J; Hellard M; Stoové M; Wilson D; Pedrana A; Doyle JS; Clark N; Holmes JA; Thompson AJ
    Int J Drug Policy; 2024 Mar; 125():104317. PubMed ID: 38281385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barriers to hepatitis C treatment among secondary needle and syringe program clients and opportunities to intervene.
    Gunn J; McNally S; Ryan J; Layton C; Bryant M; Walker S; O'Mahony C; Pedrana A
    Int J Drug Policy; 2021 Oct; 96():103387. PubMed ID: 34330571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study.
    Conway A; Valerio H; Alavi M; Silk D; Treloar C; Hajarizadeh B; Marshall AD; Martinello M; Milat A; Dunlop A; Murray C; Prain B; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Christmass M; Wade A; Montebello M; Dore GJ; Grebely J;
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
    Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P
    Int J Drug Policy; 2023 Apr; 114():103982. PubMed ID: 36863287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
    Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J;
    Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
    Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
    J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
    Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
    J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study.
    Valerio H; Conway A; Alavi M; Treloar C; Silk D; Murray C; Henderson C; Amin J; Read P; Degenhardt L; Christmass M; Montebello M; Dore GJ; Grebely J;
    Int J Drug Policy; 2022 Dec; 110():103876. PubMed ID: 36240657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.
    Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Bajis S; Valencia BM; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J
    Int J Drug Policy; 2023 Jan; 111():103917. PubMed ID: 36542883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does a simplified algorithm and integrated HCV care model improve linkage to care, retention, and cure among people who inject drugs? A pragmatic quality improvement randomized controlled trial protocol.
    Klaman SL; Godino JG; Northrup A; Lewis SV; Tam A; Carrillo C; Lewis R; Matthews E; Mendez B; Reyes L; Rojas S; Ramers C
    BMC Infect Dis; 2024 Jan; 24(1):105. PubMed ID: 38238686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychosocial Factors and the Care Cascade for Hepatitis C Treatment Colocated at a Syringe Service Program.
    Winetsky D; Burack D; Antoniou P; Garcia B; Gordon P; Scherer M
    J Infect Dis; 2020 Sep; 222(Suppl 5):S392-S400. PubMed ID: 32877544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An on-site community-based model for hepatitis C screening, diagnosis, and treatment among people who inject drugs in Kerman, Iran: The Rostam study.
    Mirzazadeh A; Hosseini-Hooshyar S; Shahesmaeili A; Sharafi H; Shafiei M; Zarei J; Mousavian G; Tavakoli F; Ghalekhani N; Shokoohi M; Khezri M; Mehmandoost S; Shojaei MR; Karamouzian M; Briceno A; Morris MD; Alavian SM; Haghdoost AA; Sharifi H; Page KA
    Int J Drug Policy; 2022 Apr; 102():103580. PubMed ID: 35074607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis.
    Trickey A; Fajardo E; Alemu D; Artenie AA; Easterbrook P
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):253-270. PubMed ID: 36706775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Point-of-care hepatitis C screening with direct access referral to improve linkage to care among halfway house residents: a pilot randomised study.
    Hsiang JC; Sinnaswami P; Lee MY; Zhang MM; Quek KE; Tan KH; Wong YM; Thurairajah PH
    Singapore Med J; 2022 Feb; 63(2):86-92. PubMed ID: 32729280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of contingency management as a strategy to improve HCV linkage to care and treatment in persons attending needle and syringe programs: A pilot study.
    Norton BL; Bachhuber MA; Singh R; Agyemang L; Arnsten JH; Cunningham CO; Litwin AH
    Int J Drug Policy; 2019 Jul; 69():1-7. PubMed ID: 31003171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study.
    Conway A; Read P; Gilliver R; McNaughton T; Valerio H; Cunningham EB; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Grebely J
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36366561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.